BioSpace News Archive

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 11th Annual SVB Leerink Global Healthcare Conference.

IRADIMED CORPORATION, announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company’s outstanding common stock.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Richard Beckman, M.D., has joined Adverum as the company’s chief medical officer (CMO).

Biogen Inc. and Xbrane Biopharma AB announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® 1.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), today announced that its chief executive officer, Brian Lian, Ph.D., will participate in a fireside chat as part of the SVB Leerink 11th Annual Global Healthcare Conference.

Atara Biotherapeutics, Inc. reported the grant of an aggregate of 31,730 restricted stock units of Atara’s common stock to 10 newly hired employees and stock options to purchase an aggregate of 30,819 shares of Atara’s common stock to four such newly hired employees.

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced a preliminary estimate of certain results for the year ended December 31, 2021.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020.

Biovica, active in cancer diagnostics, announces that it has received full feedback from the FDA on its updated 510-application enabling a clear plan for the submission process.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”) and Nano Precision Medical, Inc. (“NPM”), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction.